Skip to main content

Table 3 Cox proportional hazard models of recurrence-free and overall survival among the retrospective stage III cohort

From: Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis

 

Univariate Hazard Model

Recurrence-Free Survival

Overall Survival

HR

95% CI

P-value

HR

95% CI

P-value

NY-ESO-1 Vaccine

0.555

(0.374, 0.822)

0.0034

0.507

(0.310, 0.831)

0.007

Thickness (1 mm)

1.079

(1.044, 1.116)

< 0.0001

1.101

(1.062, 1.141)

< 0.0001

Ulceration

Absent

1

  

1

  

Present

2.206

(1.490, 3.266)

< 0.0001

2.185

(1.336, 3.573)

0.0019

Undetermined

1.079

(0.600, 1.940)

0.8002

0.953

(0.413, 2.196)

0.9093

Age (1 year)

1.015

(1.002, 1.027)

0.0201

1.025

(1.008, 1.042)

0.0033

AJCC Stage

IIIA

1

  

1

  

IIIB

1.141

(0.730, 1.783)

0.5627

1.005

(0.643, 1.570)

0.9842

IIIC

1.795

(1.130, 2.850)

0.0132

1.457

(0.915, 2.319)

0.1129

 

Multivariate Hazard Model

Recurrence-Free Survival

Overall Survival

HR

95% CI

P-value

HR

95% CI

P-value

NY-ESO-1 Vaccine

0.454

(0.301, 0.685)

0.0002

0.403

(0.269, 0.604)

< 0.0001

AJCC Stage

IIIA

1

(0.561, 1.370)

 

1

  

IIIB

1.225

(0.783, 1.916)

0.3744

1.028

(0.658, 1.608)

0.9026

IIIC

2.348

(1.452, 3.797)

0.0005

1.792

(1.114, 2.883)

0.0161

Back to article page